Novel Oncolytic Immunotherapy Aims to Address Unmet Therapeutic Need for Anti–PD-1 Refractory Tumors
OncLive,
Investigators have taken strides to genetically engineer novel oncolytic immunotherapies that synergize with existing…
An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors.
Overview of attention for article published in Journal of Clinical Oncology, May 2019
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
Good Attention Score compared to outputs of the same age (74th percentile)
-
Average Attention Score compared to outputs of the same age and source
Readers on
- mendeley
- 8 Mendeley